Ruiz de Adana, Maria SAlhambra-Exposito, Maria RosaMuñoz-Garach, AraceliGonzalez-Molero, InmaculadaColomo, NataliaTorres-Barea, IsabelAguilar-Diosdado, ManuelCarral, FlorentinoSerrano, ManuelMartinez-Brocca, Maria ADuran, AnaPalomares, Rafael2023-02-082023-02-082019-12-16Ruiz de Adana MS, Alhambra-Expósito MR, Muñoz-Garach A, Gonzalez-Molero I, Colomo N, Torres-Barea I, et al. Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study. Diabetes Care. 2020 Feb;43(2):337-342http://hdl.handle.net/10668/14823To assess the impact of a telemedicine visit using the platform Diabetic compared with a face-to-face visit on clinical outcomes, patients' health-related quality of life (HRQoL), and physicians' satisfaction in patients with type 1 diabetes. PLATEDIAN (Telemedicine on Metabolic Control in Type 1 Diabetes Mellitus Andalusian Patients) (NCT03332472) was a multicenter, randomized, 6-month follow-up, open-label, parallel-group controlled study performed in patients with type 1 diabetes with suboptimal metabolic control (HbA1c At month 6, the mean change in HbA1c levels was -0.04 ± 0.5% (-0.5 ± 5.8 mmol/mol) in the CC and 0.01 ± 0.6% (0.1 ± 6.0 mmol/mol) in the IC (P = 0.4941). The number of patients who achieved HbA1c The use of telemedicine in patients with type 1 diabetes with HbA1cc <8% (<64 mmol/mol) provides similar efficacy and safety outcomes as face-to-face visits.enÁrea de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de CádizBlood glucoseDiabetes Mellitus, type 1Dose-response relationship, drugFollow-up studiesGlycated hemoglobinHumansHypoglycemiaHypoglycemic AgentsInjectionsInsulinMaleMiddle AgedOffice VisitsPrimary Health CareQuality of LifeSpainTelemedicineTreatment OutcomeYoung Adultresearch article31831473Atención primaria de saludCalidad de vidaHipoglucemiaInsulinaInyeccionesTelemedicinaVisita a consultorio médico10.2337/dc19-07391935-5548